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OBJECTIVE: To compare superior ophthalmic vein blood flow parameters measured with color Doppler imaging in
patients with congestive Graves’ orbitopathy before and after treatment and in normal controls.
METHODS: Twenty-two orbits from 12 patients with Graves’ orbitopathy in the congestive stage and 32 orbits from
16 normal controls underwent color Doppler imaging studies. Color Doppler imaging was repeated after treatment
in the group of patients with Graves’ orbitopathy, which included orbital decompression in 16 orbits and
corticosteroids in six orbits. The findings for each group were compared.
RESULTS: In the group of orbits with congestive disease, superior ophthalmic vein flow was detected in 17
orbits (anteroposteriorally in 13 and in the opposite direction in four) and was undetectable in five. After
treatment, superior ophthalmic vein flow was detected and anteroposterior in 21 and undetected in one orbit.
In normals, superior ophthalmic vein flow was detected anteroposterior in 29 orbits and undetectable in three
orbits, indicating a significant difference between groups. There was also a significant difference between
controls and congestive Graves’ orbits and between congestive orbits before and after treatment, but not
between controls and patients after treatment. A comparison of superior ophthalmic vein flow parameters
revealed a significant difference between the groups. The superior ophthalmic vein flow was significantly
reduced in the congestive stage compared with the flow parameters following treatment and in the untreated
controls.
CONCLUSIONS: Superior ophthalmic vein flow was significantly reduced in the orbits affected with congestive
Graves’ orbitopathy and returned to normal following treatment. Congestion appears to be a contributing
pathogenic factor in the active inflammatory stage of Graves’ orbitopathy.
KEYWORDS: Color Doppler imaging; Graves’ orbitopathy; Superior ophthalmic vein; Congestive orbitopathy;
Endocrine exophthalmos.
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INTRODUCTION
Graves’ orbitopathy (GO) is an autoimmune inflamma-
tory process that affects the periorbital and orbital tissues,
mainly the extraocular muscles. The enlargement of these
muscles is responsible for most of the manifestations of the
disease, including lid retraction, proptosis, extraocular
muscle restriction, dysthyroid optic neuropathy, and con-
gestive signs such as conjunctival hyperemia, chemosis, and
lid swelling.1,2 GO occurs before, during, or after the onset
of hyperthyroidism and, less frequently, in euthyroid or
hypothyroid patients.
GO is divided into a congestive stage and a fibrotic stage.
In the congestive or inflammatory stage, autoimmunity is
believed to play a key role in the process leading to
inflammatory cellular infiltration of the muscles and
transformation of fibroblasts into adipose tissue. The fibrotic
stage is characterized by fibrosis in the orbital tissues with
residual manifestations of the disease such as proptosis and
strabismus.3,4
The pathogenesis of the acute inflammatory stage has
been attributed to autoimmunity, and treatment of patients
in this stage has traditionally been based on corticosteroids
and radiotherapy. Superior orbital vein (SOV) congestion
also plays an important role in the inflammatory stage, as
demonstrated by computed tomography5-7 and color
Doppler imaging (CDI) studies.8-11 In a recent study using
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CDI, we demonstrated that SOV flow was significantly
reduced in orbits with congestive GO and with myogenic
fibrotic GO, but not in orbits with fibrotic lipogenic
orbitopathy.11 This finding was consistent with previous
studies using CDI in patients with GO at different
stages.8-10,12 Our previous study lends support to the notion
that venous congestion plays a significant role in the
pathogenesis of the active stage of the orbitopathy and
suggests that patients can benefit from relief of SOV
congestion by clinical or surgical treatment.11 To our
knowledge, however, no previous study has evaluated
CDI flow parameters in patients with congestive orbito-
pathy before and after clinical and/or surgical treatment of
the disease. The purpose of this study was to evaluate SOV
blood flow parameters using CDI in patients with active GO
before and after treatment of the disease. We investigated
the effect of treatments such as orbital decompression and/
or corticosteroids in CDI-measured SOV flow parameters.
METHODS AND MATERIALS
This interventional, prospective, and cross-sectional study
was conducted between October 2005 and September 2010.
The study followed the principles of the Declaration of
Helsinki. Approval from the Institutional Review Board
Ethics Committee was obtained, and all of the participants
gave their informed consent.
A total of 12 patients (seven men, five women) with
congestive GO were examined. The mean age of the patients
was 53.2 (SD 9.5) years. The diagnosis of GO was
established according to previously published criteria.1 All
of the patients had Graves’ disease but became euthyroid
under treatment. Sixteen normal subjects (four men, twelve
women), with a mean age of 48.1 (SD 10.9) years, were
included in the study as a control group. The normal
subjects were defined as healthy euthyroid volunteers
without ocular diseases.
The patients underwent a complete ophthalmic examina-
tion that included best corrected visual acuity, applanation
tonometry, pupillary reactions, extraocular motility evalua-
tion, slit lamp examination, evaluation of eyelid and soft
tissue inflammation, measurement of the lid fissure, Hertel
exophthalmometry, fundoscopy, and visual field evaluation
with standard automated perimetry using the 24-2 SITA-
Standard strategy (Humphrey Field Analyzer, Carl-Zeiss
Meditec, Dublin, CA). Goldmann manual perimetry was
also used when necessary to confirm optic nerve involve-
ment. Both orbits of the patients were scanned with a
16-slice multidetector computed tomography scanner
(Brilliance 16; Philips Medical Systems, Nederland B.V.,
the Netherlands).
GO was classified as active (congestive) or fibrotic
according to a 10-item clinical activity score based on four
of five well-known classical signs of inflammation (pain,
redness, swelling, and impaired function). The clinical
activity score included orbital pain, redness of the eyelid
or conjunctiva, swelling of the conjunctiva (chemosis),
caruncle, or eyelid and impaired function represented by
decreased visual function or decreased eye movement.3 One
point was given per eye for each item present. The
evaluated items corresponded to symptoms (orbital ache
and gaze-evoked pain), signs (conjunctival redness, eyelid
erythema, eyelid edema, chemosis, and swelling of the plica
or caruncle) and indications of progressive disease in at
least two examinations.3,13 Patients with active congestive
disease had a clinical activity score of four or more points,
whereas patients classified with fibrotic disease, not
included in this study, had a clinical activity score equal
to or lower than two. To avoid any possible doubt regarding
disease activity in this study, patients with a score of three
were also excluded. Eye movement restrictions in the field
of action of the superior rectus muscle (elevation) due to
inferior rectus restriction and of the lateral rectus muscle
(abduction) due to medial rectus restriction were graded
from 0 (no limitation) to 4 (absence of eye movement from
primary position in the muscle’s field of action). Grade 1, 2
and 3 restrictions indicated 75%, 50%, and 25% excursion,
respectively, from the primary position, either by elevation
(restriction caused by the inferior rectus) or by abduction
(restriction of the medial rectus). A combined restriction
index ranging from 0 to 8 was calculated by adding the two
scores. Orbits were also classified according to the presence
or absence of dysthyroid optic neuropathy. The diagnostic
criteria for dysthyroid optic neuropathy were diminished
best corrected visual acuity not caused by changes in
transparency, presence of a relative afferent pupillary defect
and presence of visual field defect on automated or
Goldmann perimetry. To qualify as an abnormal visual
field on standard automated perimetry, at least three
adjacent abnormal points at the p,0.05 level or two adjacent
points with one abnormal at the p,0.01 level on the pattern
deviation plot were required.14 On the Goldmann perime-
try, visual field was considered abnormal in the presence of
central or paracentral scotoma, localized depression of the
isopters greater than 10 degrees or generalized constriction
of the isopters.15,16 When visual acuity was normal and
visual field abnormalities were present on standard auto-
mated perimetry, a repeat examination using automated or
the Goldmann manual perimetry was performed in order to
rule out false-positive results. All clinical assessments were
performed within one week of the CDI study.
After the ophthalmic examination, the patients were
transferred to the Radiology Department for CDI with a
6-12 megahertz linear-array transducer coupled to a Logiq 9
Doppler scanner from General Electric (Santa Clara,
California, USA). Maximum and minimum blood flow in
the SOV was determined in both eyes with the patient
resting on a bed with 30 degrees head elevation. During the
examination, the patients were asked to remain still with
both eyes closed and to fixate straight ahead. The transducer
was gently placed over the closed eyes (right eye first), and
care was taken to avoid applying pressure to the eye. Blood
flow velocity was measured in the superior nasal part of the
SOV, anterior to the point where it crosses the optic nerve.
Velocity was measured in each vessel several times until
obtaining at least two good readings, maintaining the angle
between the sound beam and the blood flow direction less
than 30 degrees. Only the highest values were used for
statistical analysis. All CDI measurements were performed
by the same experienced professional (JEB) who was
blinded to the clinical status of the patients with GO.
Maximum and minimum SOV blood flow velocities were
registered, and the mean values and standard deviations
were calculated.
All of the patients underwent treatment of congestive
disease. Sixteen orbits were treated with two-wall orbital
decompression, and six were treated with corticosteroids.
CDI studies were repeated from 6-36 months after treatment
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of congestive disease. After treatment, GO was inactive in
all orbits according to the clinical activity score classification
(a score of two or less).
Statistical analysis
The descriptive statistics included mean values ¡ SD for
normally distributed variables after the analysis of histo-
grams and the Shapiro-Wilk test confirmed the normality
assumption. We used an unpaired t-test for comparisons
of the three groups (normal controls, active GO before
treatment and GO after treatment) and a paired t-test for
comparison of active GO before and after treatment.
Each group of orbits was initially classified according to
whether the flow in the SOV was anteroposterior, absent
(not detected), or posteroanterior (reverse). The observed
proportions were compared using Fisher’s exact test. For
further statistical analyses, the anteroposterior flow was
expressed in positive numbers, undetected flow was
assigned a value of zero, and the posteroanterior flow was
expressed in negative numbers. A p value of less than .05
was considered statistically significant.
RESULTS
A total of 76 CDI studies were performed: 22 orbits from
12 patients (seven men and five women, mean age ¡ SD:
53.1¡9.5 years) with active GO (clinical activity score index
of four or higher), the same 22 orbits after treatment (activity
score index of two or less), and 32 orbits from 16 control
subjects (twelve women and four men; mean age ¡ SD:
48.3¡10.9). There was no significant age difference between
the patients and controls (p= 0.231). Before treatment, the
exophthalmometry measurements ranged from 22 to 28 mm
(mean ¡ SD: 25.52¡1.96 mm) in GO patients, and the
restriction index ranged from 0 to 8 (mean¡ SD: 5.0¡1.93).
Before treatment, 21 orbits of patients with GO were
categorized as having predominantly myogenic disease
(with a restriction grade of 3-8). One orbit was categorized
as having predominantly lipogenic disease (with muscle
restriction graded as 0). In addition, 15 orbits presented with
dysthyroid optic neuropathy before treatment.
In the normal controls, SOV was detected in 29 orbits and
was undetectable in three. Reverse blood flow was not
observed. In orbits with active congestive disease, SOV flow
was absent in five, present in 13 and reversed in four orbits
before treatment. After treatment, SOV flow in the same 22
orbits was anteroposterior (n = 21) or undetectable (n = 1)
(Table 1). A significant difference was found between GO
orbits before treatment and the control orbits (p= 0.007,
Fisher’s exact test). No significant difference was found
between the GO orbits after treatment and the control orbits
(p= 0.638).
Table 2 compares SOV flow values for the two GO groups
and for normal controls. The results of the unpaired t-test
revealed a significant difference between GO patients before
treatment and controls with regard to the maximum
(p= 0.009), minimum (p= 0.013), and differential (p= 0.005)
SOV flow. There was no significant difference between the
GO patients after treatment and the controls with regard to
the maximum, minimum, and differential flow (p= 0.703,
0.599 and 0.969, respectively). The paired t-test revealed a
significant difference in the maximum (p=0.007), minimum
(p= 0.012) and differential (p= 0.006) SOV flow in GO
patients before and after treatment (Table 2).
DISCUSSION
Autoimmunity is likely the primary mechanism involved
in the pathogenesis of Graves’ orbitopathy. It is, however,
suspected that orbital venous blood flow congestion
contributes to the development of clinical signs and
symptoms (e.g., proptosis, muscle restriction, periorbital
swelling, and chemosis) during the active stage of the
disease,17 as suggested by a number of clinical and
experimental findings. Previous studies have reported
prompt improvement in congestive signs after orbital
decompression, suggesting that venous congestion is an
important factor in the pathogenesis of the disease.18 In
another study, venous drainage impairment and subsequent
resolution was visible on fluorescein angiographs of the
optic discs from patients with dysthyroid optic neuropa-
thy.19 Hudson et al.6 suggested that the orbital SOV
enlargement observed on computed tomography scans
of patients with dysthyroid optic neuropathy may be a
contributing factor in the development of optic nerve
impairment. A previous study indicated that experimentally
induced orbital venous stasis can closely mimic many of the
clinical changes that occur in GO.17
CDI allows simultaneous imaging of the anatomic
structures by B-mode ultrasonography with superimposed
color-coded vascular flow. The current study confirmed a
significant difference in CDI parameters between patients
with GO in the active stage and controls or orbits with GO
following treatment. Reverse and absent blood flow were
observed in four and five out of 22 orbits with active GO,
respectively. Flow may be undetectable in eyes of normal
controls for several reasons, including insufficient sensitiv-
ity of the device for measuring very small venous flow rates,
or anatomic flow variations. In abnormal orbits, absent flow
is most often related to the impairment of venous return at
the orbital apex, leading to a venous flow of zero or close to
Table 1 - Detection and direction of blood flow in the superior ophthalmic vein using color Doppler imaging in patients
with Graves’ orbitopathy and control subjects.
Superior orbital vein blood flow
Anteroposterior Posteroanterior (reverse) Not detected Number of orbits
Orbitopathy before treatment * 13 (59.1%) 4 (18.2%) 5 (22.7%) 22 (100%)
Orbitopathy after treatment { 21 (95.4%) 0 (0.0%) 1 (4.5%) 22 (100%)
Controls *{ 29 (90.6%) 0 (0.0%) 3 (9.4%) 32 (100%)
Total 63 (82.9%) 4 (5.3%) 9 (11.8%) 76 (100%)
*Fisher’s exact test (p=0.007, controls compared with orbitopathy before treatment).
{Fisher’s exact test (p=0.638, controls compared with orbitopathy after treatment).
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zero. Although flow may occasionally be absent in normal
subjects, we believe the absence of flow is most likely an
indication of venous congestion. In our study, a direct
comparison revealed the absence of flow in five of 22
congestive GO orbits but only in three out of 32 normal
controls and one of 22 GO orbits after treatment.
Conversely, reverse blood flow has not been reported in
normal subjects20 and may indicate more severely impaired
orbital venous drainage. While reverse blood flow occurred
in four of 22 active GO orbits, it did not occur in any of the
32 control orbits or in the 22 GO orbits following treatment.
A comparative analysis of our groups also indicated that
SOV was significantly reduced in orbits with congestive GO
compared with control orbits or the GO orbits following
treatment, suggesting that venous congestion is most likely
a contributing factor to the pathogenesis of this condition.
Our findings of reduced SOV flow in patients with active
GO are consistent with results from several previous
studies. Nakase et al.8 found reversed SOV flow in 15% of
39 orbits with GO, but not in controls (n = 22). Reversed SOV
flow was present in 36% of 14 orbits with GO and apical
crowding. Nakase et al. suggested that these findings were a
strong indication of severe venous stasis in the orbits,
possibly related to the development of dysthyroid optic
neuropathy. No data were provided, however, regarding
the disease activity status of each orbit. Benning et al.12
found a significantly smaller maximum SOV blood flow
velocity in patients with GO than in normal subjects and a
slight correlation between reduced venous outflow in the
SOV and disease severity. Somer et al.10 used CDI in 48
orbits of 24 patients with GO and in 20 orbits of 10 healthy
volunteers. The authors found the mean venous blood flow
velocity to be significantly decreased in patients with GO.
No SOV flow, however, was detected in 18 orbits with GO.
Alp et al.9 performed CDI on 111 patients with Graves’
disease and 46 healthy controls. Patients with Graves’
disease were divided into two groups: 69 with GO and 42
with no orbitopathy. Reverse blood flow in the SOV was
observed in 13% of patients with GO. The authors found
blood flow velocities in the ophthalmic artery and the
central retinal artery to be significantly higher in patients
with GO than in orbitopathy-free patients with Graves’
disease or healthy controls. Blood flow was significantly
reduced in the SOV. The study included only patients who
were not receiving local or systemic treatment for GO, and
no disease activity criteria were provided.
Despite reporting significant changes in orbital blood
flow in patients with GO, none of the aforementioned
studies were designed to directly compare findings for
different forms of GO. Only a few studies have attempted to
correlate disease activity, based on the clinical activity
score,13 with CDI blood flow parameters. Yanik et al.21
studied 118 patients with Graves’ disease, 25 without
orbitopathy and 93 with activity-scored GO.13 The authors
found a negative correlation between orbital blood flow
parameters and their clinical activity scores.21 They
excluded patients requiring urgent orbital decompression
or receiving systemic medication, thereby likely excluding
subjects with more severe forms of orbitopathy. The study
did not separate patients in predominantly myogenic or
lipogenic forms of the disease. In a recent study, we
evaluated patients with GO after clearly distinguishing
between active and inactive as well as between myogenic
(restrictive) and lipogenic (non-restrictive) GO.14 Our find-
ings indicated that most patients with congestive GO had
reduced or reversed maximum SOV flow. Patients with
fibrotic GO in the myogenic form also displayed a
significant reduction in SOV flow compared with normal
controls. Patients with fibrotic lipogenic disease did not
differ significantly from the controls.
In the current study, we compared the same group of
active GO patients before and after treatment. The results
indicated dramatic differences in the SOV flow parameters
between the active stage of the disease and post-treatment
GO or normal controls, indicating that venous congestion is
an important element in the active stage of the disease.
The CDI data provided by this study and by previous
studies may be useful for the management of GO. Treatment
of GO in the acute stage is traditionally immunosuppressive
(using corticosteroids or immunosuppressants), but con-
gestive signs sometimes remain despite adequate treatment
and may require orbital decompression. Persistently
reduced or reversed SOV blood flow despite adequate
treatment may be an indication for decompressive surgery
in select patients. The current data appear to confirm this
assumption, as most of our patients were in fact treated with
orbital decompression.
In conclusion, the fact that SOV flow was significantly
reduced in the congestive stage of GO and normalized after
treatment of active orbitopathy suggests that venous
congestion plays a significant role in the pathogenesis of
the disease. Our data lends support to the notion that
clinical improvement with treatment is due to the control of
not only the autoimmune process but also orbital venous
congestion. On the basis of these findings, we believe that if
diminished SOV flow persists despite adequate clinical
treatment, orbital decompression should be considered to
improve congestive signs. Further studies with more
Table 2 - Comparison of blood flow parameters in the superior ophthalmic vein (SOV) in patients with Graves’
orbitopathy and controls.
Mean (range) velocity (cm/s)
SOV maximum velocity * SOV minimum velocity * Differential flow velocity *
Congestive GO before
treatment (22 orbits)
3.07*{
(-13.16 – 9.55)
2.11*{
(-10.0 – 7.26)
0.96*{
(-4.22 – 6.66)
GO after treatment
(22 orbits)
7.80 *
(0 – 11.96)
5.31 *
(0 – 8.75)
2.48 *
(0 – 4.43)
Normals
(32 orbits)
7.49 {
(0 – 11.68)
5.02 {
(0 – 8.91)
2.47 {
(0 – 5.48)
*p,0.05, paired t-test, comparing GO orbits before and after treatment.
{p,0.05, unpaired t-test, active GO compared with controls.
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patients are necessary confirm these findings and to better
evaluate potential differences in congestion relief between
clinical and surgical treatment of the congestive stage of GO.
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